MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
+0.100
+2.44%
After Hours: 4.190 -0.01 -0.24% 19:00 08/07 EDT
OPEN
4.110
PREV CLOSE
4.100
HIGH
4.200
LOW
4.035
VOLUME
240.97K
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.7332
MARKET CAP
103.75M
P/E (TTM)
-14.4828
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EVOK stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

EPS

EVOK News

More
Evoke Pharma EPS misses by $0.20
Evoke Pharma (NASDAQ:EVOK): Q2 GAAP EPS of -$0.28 misses by $0.20. Cash and cash equivalents of $7.99M. Press Release
seekingalpha · 1d ago
Evoke Pharma Reports Second Quarter 2020 Financial Results
Preparing for commercial launch of GIMOTI™ in 4Q 2020SOLANA BEACH, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its fin
GlobeNewswire · 1d ago
Evoke Pharma Initiates Commercial Manufacturing of Gimoti
Benzinga · 07/15 12:30
Evoke Pharma Initiates Commercial Manufacturing of Gimoti™
SOLANA BEACH, Calif., July 15, 2020 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.
GlobeNewswire · 07/15 12:30
Evoke Pharma Extends Cash Runway to 2Q 2021
GlobeNewswire · 07/08 13:30
Evoke Pharma Says As Of Jun. 30 Had Cash And Equivalents Of ~$8M; Preparing To Initiate Commercial Sales Of GIMOTI In Q4
SOLANA BEACH, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that as of June 30,
Benzinga · 07/08 12:40
The End Of A Record Green Streak, The Beginning Of Something New
After weeks of talking about it and anticipating what my total might look like at the end of it, I’ve finally managed to top the longest green streak of my career with the highest daily profit of my career.
Benzinga · 06/26 19:10
Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So
SmarterAnalyst · 06/26 03:58

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About EVOK

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
More

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.